文献速递药物不良反应与药物警戒

药物警戒风险评估委员会(PRAC)工作解读:2012至2022年抗糖尿病药物上市后安全性评价定量综述

Understanding the Work of the Pharmacovigilance Risk Assessment Committee (PRAC): A Quantitative Review of the Post-Authorisation Safety Evaluation of Antidiabetic Drugs from 2012 to 2022.
PubMed 文献 · Drug Saf · 2025-03-01

该研究基于PRAC会议纪要,定量分析2012至2022年抗糖尿病药物相关不良事件评价,共识别321个药物-不良事件对,涉及413次评价。结果显示48%评价无需监管措施,97%评价在单一程序中完结,66%在一次会议内完结;定期安全性更新报告占54%,产品信息更新为最常见结果。信号评估与优先排序程序虽较少,但产生更多样化的监管建议。

要点

  • 定期安全性更新报告是PRAC评价安全信号的主要来源,占54%评价。
  • 信号评估与优先排序程序虽少,但产生更多样化监管行动,含转介。
  • 48%的药物-不良事件评价未导致监管措施,多数评价在单次程序或会议内完结。

核心结论

  • 定期安全性更新报告是PRAC评价安全信号的主要来源,但并非用于通报新的紧急安全性信息。
  • 与定期安全性更新报告相比,信号评估与优先排序程序评估的信号更少,但导致更广泛的监管行动,从风险最小化措施到转介。

研究设计与样本

  • 基于PRAC会议纪要的定量综述,检索2012至2022年所有抗糖尿病药物相关不良事件讨论。
  • 共识别321个药物-不良事件对,其中62对经历多次评价,共产生413次评价。

主要发现

  • 第二代抗糖尿病药物,包括SGLT-2抑制剂、GLP-1受体激动剂和DPP-4抑制剂,是讨论最频繁的药物类别。
  • 48%的评价无需监管措施;97%的评价在单一程序中完结,66%在一次会议内完结。
  • 定期安全性更新报告占药物-不良事件评价的54%,产品信息更新是最常见的结果。
  • 信号评估与优先排序程序较少见,但产生更多样化的监管行动建议;转介不频繁(N=5),常由信号评估与优先排序程序触发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Pharmacovigilance Risk Assessment Committee (PRAC) plays a central role in the European Union's pharmacovigilance system, evaluating drug safety through several procedures and activities. Despite its central role, few studies have quantitatively investigated the PRAC's activities from a system's perspective. OBJECTIVE: This study aims to map PRAC's evaluation of safety signals and concerns using antidiabetic products as a case. It characterises the drugs and adverse events involved, analyses the PRAC-led regulatory procedures where the safety signals and concerns were evaluated, and provides a comprehensive review of PRAC meeting minutes. METHODS: From PRAC meeting minutes, we retrieved information on all antidiabetic drug-related adverse events discussed from 2012 to 2022. We identified drug-adverse event evaluations based on the discussion content. These were described by drug classes, System Organ Classes, PRAC procedures, and the evaluation outcomes corresponding to recommendations for regulatory actions. We also analysed the sequence of PRAC-led procedures and activities addressing drug-adverse event pairs across meeting minutes. RESULTS: A total of 321 drug-adverse event pairs were identified, with 14 pairs associated with drug classes. Second-generation antidiabetic agents, including sodium-glucose transport protein-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase 4 inhibitors, were the most frequently discussed. Of these, 62 pairs underwent multiple evaluations, resulting in a total of 413 evaluations. In 48% of evaluations, no regulatory action was required. Most evaluations (97%) were concluded in a single procedure, and 66% were concluded in one meeting. Periodic safety update reports accounted for 54% of drug-adverse event evaluations and updates to product information were the most frequent outcome. Signal assessment and prioritisation procedures, while less common, resulted in more diverse recommendations for regulatory action. Referrals were infrequent (N = 5) and were often triggered by the signal assessment and prioritisation procedure. CONCLUSIONS: Periodic safety update reports are the primary source for PRAC evaluations of safety signals although they are not intended for notification of new urgent safety information. Compared with periodic safety update reports, the signal assessment and prioritisation procedure evaluates fewer signals but leads to a wider range of regulatory actions, from risk minimisation measures to referrals. This difference may be attributed to the fact that signals detected in periodic safety update reports are not intended for urgent safety issues, these should be assessed through the signal assessment and prioritisation procedure, as the latter involves real-time signal management, whereas the periodic safety update reports are conducted at predefined intervals.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Le H, Sindahl P, Andersen M, et al. Understanding the Work of the Pharmacovigilance Risk Assessment Committee (PRAC): A Quantitative Review of the Post-Authorisation Safety Evaluation of Antidiabetic Drugs from 2012 to 2022. Drug Saf. 2025. PMID: 40024970. doi:10.1007/s40264-025-01536-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。